NewsRx

Search our medical news database

Drug Development

Drug developer sets $15 million financing, renin inhibitor collaboration

Published in Blood Weekly, August 18th, 2005

Vitae Pharmaceuticals announced that its recent licensing and development agreement with GlaxoSmithKline (GSK) has met its closing conditions, including U.S. Federal Trade Commission (FTC) clearance under the Hart-Scott-Rodino Act.

As part of the formal completion of the transaction with GSK, Vitae secured $15 million in equity financing from investors, which the company intends to use principally to accelerate its multiple programs into the clinic.

GSK and Vitae formed a strategic alliance in June 2005 to develop and commercialize renin inhibitor drug compounds for the treatment of hypertension and related cardiovascular disorders. As part of this...

Want to see the full article?

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Buy Now


Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly


NewsRx is Social

Follow us on your favorite social network by clicking on a button below:

Follow NewsRx on Twitter

NewsRx on Facebook

Awards

eHealthcare Leadership 2011 Winner
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

  • Google 2010 PageRank: #2 Among Top Health News and Media Publications
  • Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
  • Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
  • Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx on Facebook